2020
Sex differences in immune responses that underlie COVID-19 disease outcomes
Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, Silva J, Mao T, Oh JE, Tokuyama M, Lu P, Venkataraman A, Park A, Liu F, Meir A, Sun J, Wang EY, Casanovas-Massana A, Wyllie AL, Vogels CBF, Earnest R, Lapidus S, Ott IM, Moore AJ, Shaw A, Fournier J, Odio C, Farhadian S, Dela Cruz C, Grubaugh N, Schulz W, Ring A, Ko A, Omer S, Iwasaki A. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 2020, 588: 315-320. PMID: 32846427, PMCID: PMC7725931, DOI: 10.1038/s41586-020-2700-3.Peer-Reviewed Original ResearchConceptsInnate immune cytokinesFemale patientsMale patientsImmune cytokinesDisease outcomeImmune responseCOVID-19COVID-19 disease outcomesPoor T cell responsesSARS-CoV-2 infectionSevere acute respiratory syndrome coronavirusAcute respiratory syndrome coronavirusSex-based approachModerate COVID-19Sex differencesRobust T cell activationT cell responsesWorse disease progressionWorse disease outcomesHigher plasma levelsNon-classical monocytesCoronavirus disease 2019T cell activationImmunomodulatory medicationsPlasma cytokinesShort-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade
Ajona D, Ortiz-Espinosa S, Lozano T, Exposito F, Calvo A, Valencia K, Redrado M, Remírez A, Lecanda F, Alignani D, Lasarte J, Macaya I, Senent Y, Bértolo C, Sainz C, Gil-Bazo I, Eguren-Santamaría I, Lopez-Picazo J, Gonzalez A, Perez-Gracia J, de Andrea C, Vicent S, Sanmamed M, Montuenga L, Pio R. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade. Nature Cancer 2020, 1: 75-85. PMID: 35121837, DOI: 10.1038/s43018-019-0007-9.Peer-Reviewed Original ResearchConceptsPD-1 blockadeCell death protein 1 (PD-1) pathwayPD-1 immune checkpoint blockadeCD8/Treg ratioHigh IGF-1R expressionInsulin-like growth factor-1Cell lung cancer treatmentIGF-1 levelsPD-1 inhibitionImmune checkpoint blockadeTumor-specific immunityCell lung cancerIGF-1R expressionHigher plasma levelsLung cancer progressionLung cancer treatmentIGF-1 receptorGrowth factor-1Protein 1 pathwayTreg ratioCD8 cellsCheckpoint blockadePD-1Syngeneic modelLung cancer
2017
A Branched-Chain Amino Acid-Related Metabolic Signature Characterizes Obese Adolescents with Non-Alcoholic Fatty Liver Disease
Goffredo M, Santoro N, Tricò D, Giannini C, D’Adamo E, Zhao H, Peng G, Yu X, Lam TT, Pierpont B, Caprio S, Herzog RI. A Branched-Chain Amino Acid-Related Metabolic Signature Characterizes Obese Adolescents with Non-Alcoholic Fatty Liver Disease. Nutrients 2017, 9: 642. PMID: 28640216, PMCID: PMC5537762, DOI: 10.3390/nu9070642.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseMagnetic resonance imagingBranched-chain amino acidsFatty liver diseaseHepatic fat contentObese adolescentsInsulin resistanceLiver diseaseTwo-step hyperinsulinemic-euglycemic clampOral glucose tolerance testSecond magnetic resonance imagingSubset of patientsGlucose tolerance testHyperinsulinemic-euglycemic clampHigher plasma levelsHepatic insulin sensitivityChain amino acidsPlasma levelsTolerance testInsulin sensitivityMetabolomic signaturePlasma metabolitesResonance imagingValine levelsLipid metabolism
2016
Effect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers With Alcohol Use Disorders
Verplaetse TL, Pittman BP, Shi JM, Tetrault JM, Coppola S, McKee SA. Effect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers With Alcohol Use Disorders. Journal Of Addiction Medicine 2016, 10: 166-173. PMID: 27159341, PMCID: PMC4880525, DOI: 10.1097/adm.0000000000000208.Peer-Reviewed Original ResearchConceptsAlcohol use disorderEffects of vareniclineAlcohol consumptionUse disordersVarenicline doseD dosePlasma levelsDose of vareniclineDoses of vareniclineFrequency of insomniaPlacebo-controlled investigationHigher plasma levelsDose of alcoholAlcohol self-administrationSelf-administration periodMedication pretreatmentAdverse eventsEdition criteriaVareniclineLow doseSide effectsAlcohol cravingMeeting criteriaPhysiologic responsesAlcohol-related outcomes
2015
VCAM-1 is a TGF-β1 inducible gene upregulated in idiopathic pulmonary fibrosis
Agassandian M, Tedrow JR, Sembrat J, Kass DJ, Zhang Y, Goncharova EA, Kaminski N, Mallampalli RK, Vuga LJ. VCAM-1 is a TGF-β1 inducible gene upregulated in idiopathic pulmonary fibrosis. Cellular Signalling 2015, 27: 2467-2473. PMID: 26386411, PMCID: PMC4684430, DOI: 10.1016/j.cellsig.2015.09.003.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisVCAM-1IPF subjectsPulmonary fibrosisVascular cell adhesion molecule-1Lethal interstitial lung diseaseVCAM-1 protein levelsCell adhesion molecule-1Interstitial lung diseaseLungs of subjectsProtein levelsHigher plasma levelsVCAM-1 mRNAAdhesion molecule-1Pulmonary diffusion capacityHuman lung fibroblastsIPF lungsLung functionFibrotic fociVital capacityLung diseaseUnknown etiologyControl subjectsPlasma levelsCell cycle arrest
2001
Free insulin‐like growth factor‐I and breast cancer risk
Li B, Khosravi M, Berkel H, Diamandi A, Dayton M, Smith M, Yu H. Free insulin‐like growth factor‐I and breast cancer risk. International Journal Of Cancer 2001, 91: 736-739. PMID: 11267989, DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1111>3.0.co;2-#.Peer-Reviewed Original ResearchConceptsIGF-I receptorInsulin-like growth factorFree IGFIGFBP-3Action of IGFBreast cancer patientsTotal IGFBreast cancer riskBreast cancerIGF-IICancer patientsPlasma levelsCancer riskFree insulin-like growth factorRace-matched healthy controlsFree IGF-I levelsConditional logistic regression analysisGrowth factorIGF-I levelsIGF binding proteinBinding of IGFHigher plasma levelsLogistic regression analysisHigher plasma IGFAnti-apoptotic effects
1999
Plasma Levels of Insulin-Like Growth Factor-I and Lung Cancer Risk: a Case-Control Analysis
Yu H, Spitz M, Mistry J, Gu J, Hong W, Wu X. Plasma Levels of Insulin-Like Growth Factor-I and Lung Cancer Risk: a Case-Control Analysis. Journal Of The National Cancer Institute 1999, 91: 151-156. PMID: 9923856, DOI: 10.1093/jnci/91.2.151.Peer-Reviewed Original ResearchConceptsInsulin-like growth factorLung cancer riskHigher plasma levelsPlasma levelsIGFBP-3Lung cancerControl subjectsIGF-IICancer riskOdds ratioLevels of IGFIGFBP-3 plasma levelsGrowth factorIGFBP-3 levelsPlasma IGFBP-3Primary lung cancerIGF-binding proteinsCase-control studyLung cancer developmentCase-control analysisEnzyme-linked immunosorbentPossible causal roleIGF variablesCase patientsConsecutive patients
1997
Plasma β‐Endorphin, Adrenocorticotropin Hormone, and Cortisol in Autism
Tordjman S, McBride P, Hertzig M, Snow M, Anderson G, Hall L, Thompson S, Ferrari P, Cohen D. Plasma β‐Endorphin, Adrenocorticotropin Hormone, and Cortisol in Autism. Journal Of Child Psychology And Psychiatry 1997, 38: 705-715. PMID: 9315980, DOI: 10.1111/j.1469-7610.1997.tb01697.x.Peer-Reviewed Original ResearchConceptsAdrenocorticotropin hormoneBeta-endorphinPlasma levelsHigher plasma levelsPlasma β-endorphinNormal control individualsAcute stress responseΒ-endorphinNormal controlsControl individualsAcute stressorChronic hyperarousalStress response systemSevere autismCortisolAutistic groupHormoneIndividualsGroupHighest meanAutistic individualsLevelsStress responseReversal of in vivo drug resistance by the transforming growth factor‐β inhibitor decorin
Teicher B, Maehara Y, Kakeh Y, Ara G, Keyes S, Wong J, Herbst R. Reversal of in vivo drug resistance by the transforming growth factor‐β inhibitor decorin. International Journal Of Cancer 1997, 71: 49-58. PMID: 9096665, DOI: 10.1002/(sici)1097-0215(19970328)71:1<49::aid-ijc10>3.0.co;2-4.Peer-Reviewed Original ResearchConceptsEMT-6/CDDP tumorTumor cell survivalParent tumorResistant tumorsDrug resistanceAdministration of decorinCell survivalEMT-6/CTXPlasma TGF-beta levelsTGF-beta proteinGranulocyte-macrophage colony-stimulating factorSitu hybridizationTGF-beta levelsVivo drug resistanceHigher plasma levelsTGF-beta mRNATumor-bearing animalsMurine mammary tumorsGrowth factorColony-stimulating factorDrug responseDecorinCytotoxic therapyPlasma levelsTumor levels
1989
Sustained High‐Dose Nitroglycerin Transcutaneous Patch Therapy in Angina Pectoris: Evidence for Attenuation of Effect Over Time
Frishman W, Giles T, Greenberg S, Heiman M, Raffidal L, Soberman J, Laifer L, Nadelmann J, Lazar E, Strom J. Sustained High‐Dose Nitroglycerin Transcutaneous Patch Therapy in Angina Pectoris: Evidence for Attenuation of Effect Over Time. The Journal Of Clinical Pharmacology 1989, 29: 1097-1105. PMID: 2515215, DOI: 10.1002/j.1552-4604.1989.tb03285.x.Peer-Reviewed Original ResearchConceptsPlasma nitroglycerin levelsWeek 1Blood pressurePatch therapyHeart rateSerial treadmill testingChronic stable anginaDouble-blind fashionSystolic blood pressureHigher plasma levelsAttenuation of effectsDrug-free baselineIntolerable headacheMg/24 hoursMmHg reductionTitration doseDosing intervalExercise toleranceStable anginaAngina pectorisPlacebo patchTreadmill testingSublingual nitroglycerinPlasma levelsVenous blood
1987
Aldosterone increases the maximal turnover rate of the sodium pump
Halevy J, Boulpaep E, Binder H, Hayslett J. Aldosterone increases the maximal turnover rate of the sodium pump. Pflügers Archiv - European Journal Of Physiology 1987, 410: 476-480. PMID: 3432052, DOI: 10.1007/bf00586528.Peer-Reviewed Original ResearchConceptsSodium pumpSodium transportLow sodium dietEffects of aldosteroneAdministration of aldosteroneHigher plasma levelsIntact adrenal glandsRat distal colonEquivalent short-circuit currentAddition of nystatinH aldosteroneSodium dietAdrenal glandChronic conditionsPlasma levelsDistal colonAcute actionsAldosteroneUssing chambersHours of exposureChronic exposureSame time periodApical barrierSimilar changesMucosal solution
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply